Strategic Partnerships Arima Genomics has recently secured distribution partnerships with Active Motif for exclusive rights to Hi-C kits and services, signaling a channel-driven sales opportunity to expand market reach through Epigenetics and multiomic product networks.

Clinical Validation Recognition on Fast Company’s World Changing Ideas List for the Aventa Lymphoma test and ongoing presentations at AMP Europe and the Association for Molecular Pathology indicate strong clinical credibility, which can be leveraged to pursue partnerships with hospitals, cancer centers, and reference laboratories.

Cancer Diagnostics Focus Strategic collaborations with Fox Chase Cancer Center and ongoing cancer-focused diagnostics efforts position Arima Genomics as a partner for clinics seeking 3D genome structure insights to improve therapy selection, enabling targeted outreach to oncology departments and translational researchers.

Data-Driven Proof Hi-C sequencing data demonstrating superior detection for lymphoma rearrangements presents a compelling value proposition for biotechnology firms and contract research organizations aiming to enhance genomic structural analysis offerings.

Growth Readiness With multi-figure revenue and steady funding, Arima Genomics is positioned to scale collaborations, seek larger-scale deployments, and engage strategic clients across biopharma, diagnostic labs, and academic medical centers seeking integrated DNA sequence and structure insights.